These results indicated that the combination of sorafenib and the HSP90 inhibitor ganetespib may have a synergistic inhibiting effect on AFP-expressing HCC cells, and therefore may be a potential treatment option for HCC patients. The gene discussed is HSP90AA1; the disease is hepatocellular carcinoma.